JD Supra16h
CMS's New TCET Pathway Expedites Medicare Coverage for FDA Breakthrough Devices
The Centers for Medicare and Medicaid Services ("CMS") published a final notice outlining the processes and procedures for the Transitional ...
JD Supra19h
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
RFK Jr. grilled on Medicare: What is Medicare Part A, Medicare Part B and Medicaid? What are they?
Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation ...
KHOU 1110d
Yes, Trump rescinded Biden's order to lower prescription drug costs for people on Medicare and Medicaid
CMS ultimately selected to test three models with the ... would have had Medicare pay less for drugs that receive accelerated ...
vator8h
Dr. Robert Pearl and Bambi Francisco Roizen debate how to reduce healthcare costs amid a Trump administration
In 2025, we may see radical top-down changes to our healthcare system as new heads of the NIH – National Institutes of Health ...
Fierce Healthcare19h
Trump's CMS signals flexibility on Medicare drug price negotiation, sparking new questions for RFK Jr.
The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...
Trump order signals shake-up in drug pricing innovation through Medicare and Medicaid
Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.
CNN on MSN8d
Trump administration directs federal health agencies to pause communications
Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...
The Dangers Hidden In CMS’ Drug Pricing Regulation
The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...
What’s Trump Done on Prescription Drug Prices So Far – and What Might Be Next?
An early move by the president has raised questions about what direction his second-term policy on drug costs will take.
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabetes ...